Trial Profile
Efficacy and Safety of Tocilizumab in the Treatment of Patients With Respiratory Distress Syndrome and Cytokine Release Syndrome Secondary to COVID-19: a Proof of Concept Study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Apr 2022
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Adult respiratory distress syndrome; COVID 2019 infections; Cytokine release syndrome
- Focus Proof of concept; Therapeutic Use
- Acronyms TOSCA
- 09 Apr 2020 Status changed from not yet recruiting to recruiting.
- 07 Apr 2020 New trial record